BPA Call 36E79726A0012-36C24526N0758
Award Date 7/24/26
Potential Completion Date 7/28/26
Potential Value $38K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Not listed Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Brooks, KY 40109, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- On February 5, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 MG, a specialized pharmaceutical treatment for rare genetic disorders. This firm fixed-price delivery order is issued under a parent Blanket Purchase Agreement established on the General Services Administration Pharmaceuticals and Drugs Schedule (FSS-61-IB), which provides streamlined...
- On December 16, 2025, the Department of Veterans Affairs Veterans Integrated Service Network 5 awarded a firm fixed-price delivery order valued at $36,984.28 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 mg, a specialized pharmaceutical treatment for hereditary angioedema. This delivery order represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and carries an ultimate completion date of December 18, 2025. The contract was awarded...
- On November 7, 2025, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a firm fixed-price delivery order valued at $36,984.28 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. This delivery order represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and carries an ultimate completion date of November 13, 2025. The award was made without a...
- This is a firm fixed-price delivery order awarded to Takeda Pharmaceuticals America Inc. by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 5 (VISN 5). The contract is for the delivery of TAKHZYRO 150 MG, a specialized pharmaceutical product, with a ceiling value of $36,984.28 and a period of performance through August 5, 2025. The contract is not set aside and is awarded under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule...
- This delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awards Takeda Pharmaceuticals America Inc. a $36,890.40 firm fixed price contract to supply TAKHZYRO 150MG/ML SYRINGE 2ML PER SYRINGE with a quantity of 2. The contract is issued against Takeda Pharmaceuticals America Inc.'s existing Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), with performance taking place in Lexington, Massachusetts. No...
- Takeda Pharmaceuticals America Inc. was awarded a $36,984.28 firm fixed-price delivery order for TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. The contract, issued on October 16, 2025, with an ultimate completion date of October 17, 2025, is a child order under Takeda's broader Blanket Purchase Agreement with the VA National Acquisition Center valued at $131.04 million. The award was issued without a set-aside designation, reflecting the specialized and...
- The Department of Veterans Affairs (VA) awarded a firm fixed-price delivery order contract to Takeda Pharmaceuticals America Inc., a subsidiary of Takeda Pharmaceutical Company LIMITED, for the supply of the specialty pharmaceutical TAKHZYRO. The contract has a potential value of $36,890.40 and a completion date of April 24, 2024. Takeda Pharmaceuticals America Inc. is a prime contractor that provides a range of pharmaceutical products, including those to treat hemophilia, immune disorders,...
- The Department of Veterans Affairs Veterans Health Administration awarded Takeda Pharmaceuticals America Inc. a $36,101.68 firm fixed price delivery order against the company's GSA Schedule contract for Pharmaceuticals and Drugs. The delivery order is for TAKHZYRO 150MG/ML SYRINGE 2ML SYRINGE (2) to be supplied to Veterans Integrated Service Network 9, with performance taking place in Lexington, Massachusetts from September 6-7, 2023. As the prime contractor, Takeda Pharmaceuticals America...
- This federal contract award is for the pharmaceutical product TAKHZYRO 150 MG, which was awarded to Takeda Pharmaceuticals America Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The contract, valued at $36,984.28, is a delivery order with a firm fixed-price pricing type, and the ultimate completion date is August 27, 2025. The contract was awarded by the Veterans Integrated Service Network 5, a civilian defense agency, and is part of the General...
- The Department of Veterans Affairs Veterans Health Administration awarded Takeda Pharmaceuticals America Inc. a $36,101.68 firm fixed price delivery order for TAKHZYRO 150MG/ML syringes. Takeda Pharmaceuticals America Inc. will deliver the syringes to a location in Lexington, Massachusetts by September 21, 2023 to fulfill requirements under the Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), the parent vehicle held by Takeda Pharmaceutical Company LIMITED. The funding...